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a  b  s  t  r  a  c  t
Active  global  surveillance  and  characterization  of inﬂuenza  viruses  are  essential  for  better  preparation
against  possible  pandemic  events.  Obtaining  comprehensive  information  about  the  inﬂuenza  genome
can  improve  our  understanding  of the  evolution  of inﬂuenza  viruses  and  emergence  of new  strains,
and  improve  the  accuracy  when  designing  preventive  vaccines.  This  study  investigated  the  use of
deep  sequencing  by the  next-generation  sequencing  (NGS)  Illumina  MiSeq  Platform  to  obtain  complete
genome  sequence  information  from inﬂuenza  virus isolates.  The  inﬂuenza  virus  isolates  were  cultured
from  6 respiratory  acute  clinical  specimens  collected  in Thailand  and  Nepal.  DNA  libraries  obtained  from
each  viral  isolate  were  mixed  and  all were  sequenced  simultaneously.  Total  information  of  2.6  Gbases
was  obtained  from  a 455  ± 14  K/mm2 density  with  95.76%  (8,571,655/8,950,724  clusters)  of the  clusters
passing  quality  control  (QC)  ﬁlters.  Approximately  93.7%  of  all sequences  from  Read1  and  83.5%  from
Read2  contained  high  quality  sequences  that were  ≥Q30,  a base  calling  QC  score  standard.  Alignments
analysis  identiﬁed  three  seasonal  inﬂuenza  A H3N2  strains,  one  2009  pandemic  inﬂuenza  A H1N1  strain
and  two  inﬂuenza  B strains.  The  nearly  entire  genomes  of  all six  virus  isolates  yielded  equal  or greater  than
600-fold  sequence  coverage  depth.  MiSeq  Platform  identiﬁed  seasonal  inﬂuenza  A  H3N2,  2009  pandemic
inﬂuenza  A  H1N1and  inﬂuenza  B  in  the DNA  library  mixtures  efﬁciently.
 2013©
. Introduction
Deep “next-generation sequencing” (NGS) is a powerful tool
o obtain information on quasispecies, whole genome variabil-
ty, low abundance of drug resistance mutations, and evolution
ithin the host (Barzon et al., 2011). Many platforms of NGS have
een utilized to investigate a range of questions regarding rare
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or more common viruses including Varicella zoster virus (VZV),
Epstein–Barr virus (EBV), Kaposi sarcoma-associated herpes virus
(KSHV), dengue virus and inﬂuenza virus (Depledge et al., 2011;
Yozwiak et al., 2012).
Inﬂuenza viruses, negative stranded RNA orthomyxoviridae
family viruses that cause human respiratory infections, are
causative agents of annual outbreaks around the globe with
high morbidity and mortality. Successful monitoring of inﬂuenza
virus evolution as well as preparation for future endemic events
depend on global inﬂuenza surveillance (Butler, 2012), stud-
ies of evolutionary genetics, molecular interaction of inﬂuenza
(McDonald et al., 2007; Zaraket et al., 2009), and detection of
new strains emergence such as avian or swine inﬂuenza (Dugan
et al., 2008). Different inﬂuenza strain surveillance studies have
been conducted worldwide including Europe (Zohari et al., 2008),
Central and South America (Sovero et al., 2010), South Africa
(Besselaar et al., 2004), US and Nepal (Daum et al., 2006). In
Thailand, molecular epidemiology, characterization and evolution
Open access under CC BY-NC-ND license.of inﬂuenza viruses were studied actively and played important
roles in national policy addressing inﬂuenza prevention and treat-
ment plans (Chutinimitkul et al., 2008a,b; Gibbs et al., 2009;
Suwannakarn et al., 2010; Trakulsrichai et al., 2012).
 license.
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Seasonal inﬂuenza vaccines, an essential part of strategic pre-
ention plans, are updated continuously to match circulating
trains each year. Studies on prevalence and evolution of two types
f inﬂuenza viruses (inﬂuenza virus A and B) are vital to con-
uct vaccine strain selection. The design and composition of the
nﬂuenza vaccine vary depending on any changes in the combined
engths of inﬂuenza viruses A (13.6 kb) and B (14.6 kb) genome or
ariations of the 8 genomic fragments: RNA polymerase PB1 unit
2341 nt); RNA polymerase PB2 unit (2300 nt); RNA polymerase
A unit (2233 nt); hemagglutinin (HA) (1765 nt); nucleoprotein
NP) (1565 nt); neuraminidase (NA) (1413 nt) with additional NB
rotein for inﬂuenza B; matrix (M)  (1027 nt); nonstructural pro-
ein (NS) including NS1 and the nuclear export protein (NEP) (890
t). Hence, an efﬁcient methodology of obtaining inﬂuenza virus
equence information is crucial to execute these missions.
In this study, the MiSeq Platform (NGS from Illumina) was
elected to sequence simultaneously the isolates from clinical
cute respiratory specimens collected during surveillance stud-
es in Thailand and Nepal. Procedure details starting from sample
reparation to data analysis using MiSeq Platform were investi-
ated comprehensively in order to obtain complete high quality
enome sequences of inﬂuenza A and B viruses.
. Materials and methods.1. Clinical specimens used for culturing viral isolates
The original clinical specimens were collected as nasal swabs
n Universal Transport Media-UTM (UTM) (Copan Diagnostics,
ig. 1. Procedures of RNA preparation, cDNA synthesis, DNA ampliﬁcation and sequenci
he  1st strand and 2nd strand cDNA were synthesized using SuperScript III and the secon
lunt  ends, adenylated with an adenosine at the 3′end, ligated with adapters, which we
nriched by PCR ampliﬁcation. The library mixtures were validated by nucleic acid qua
eneration. The library mixtures were denatured, complemented with internal control Ph
ere  visualized, validated for quality and converted to base calling ﬁles (*.bcl ﬁles) for seical Methods 193 (2013) 394– 404 395
Corona, USA) from volunteers with inﬂuenza-like illness in 2012,
who were diagnosed with inﬂuenza by QuickVue (Quidel, San
Diego, USA), PCR and cell culture. Five specimens (5/6) were col-
lected at Phramongkutklao (PMK) Hospital, Bangkok, Thailand. One
specimen (1/6) was obtained from Nepal during routine respira-
tory surveillance. Both studies were approved by the Institutional
Review Boards (IRB) from PMK  Hospital, the Nepal Health Research
Council, and Walter Reed Army Institute of Research (WRAIR).
For each clinical specimen, 100 l of UTM  were inoculated in
2 × 105 Madin Darby canine kidney (MDCK) cells as described pre-
viously (Klungthong et al., 2010). Each sample was cultured until
cytopathic effect (CPE) was  observed, usually requiring 3 passages
(7 days/passage) or fewer. CPE and HAI assays were conducted as
described previously (Klungthong et al., 2010).
2.2. Nucleic acid extraction from viral isolates and Illumina
sample preparation
A simple diagram of sample preparation procedures for Illu-
mina MiSeq Platform is depicted in Fig. 1. Viral RNA extraction
was performed on 140 l of cell culture virus isolate using QIAamp
Viral RNA Mini Kit (QIAGEN, Valencia, USA). Optimal quality of
the extracted RNA was veriﬁed by obtaining the OD260/OD280
values using NanoDrop (Thermo Scientiﬁc, Wilmington, USA).
RNA was  quantiﬁed using Qubit® 2.0 Fluorometer (Invitrogen,
Grand Island, USA) and 2200 TapeStation (Agilent Technologies,
Santa Clara, USA), commonly known as “bioanalyzer”. Ethanol
precipitation was  performed prior to proceeding to TruSeq LT RNA
sample preparation according to the manufacturer’s instructions.
ng by MiSeq. RNA from each isolate was puriﬁed, followed by heat fragmentation.
d strand master mix, respectively. The 3′end of each sample was repaired to create
re composed of thymidine overhangs, indexed pair-ends. The samples were then
ntiﬁcation utilizing 2200 TapeStation, Qbit and qPCR in order to optimize cluster
iX, and loaded for sequencing in the Illumina cartridge. Fluorescence images results
quence analysis.
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rieﬂy, RNA pellets from ethanol precipitates were resuspended
sing Elute, Prime and Fragment Mix  solution, followed by heat
ragmentation at 94 ◦C for 8 min. The ﬁrst strand cDNA synthesis
as conducted using SuperScript III (Life technologies, Invitrogen,
rand Island, USA) using random hexamer primers and ampliﬁed
t 25 ◦C for 10 min, 42 ◦C for 50 min, 70 ◦C for 15 min. Second
trand Master Mix  was added into the original reaction mixture to
ynthesize the second strand at 16 ◦C for 60 min. AMPure XP beads
ere utilized to purify the complete double-stranded DNA.
To maximize the ligation efﬁciency of the double-stranded DNA
o the adapters, the ends of each DNA fragment were repaired by
ncubating with End Repair Mix  at 30 ◦C for 30 min  to generate blunt
nds for all DNA fragments. The blunt-ended double-stranded DNA
as puriﬁed by AMPure XP beads. An A-Tailing Mix  was added into
he puriﬁed DNA by incubating at 37 ◦C for 30 min  to adenylate the
′ends, preventing ligation with one another. Ligation to commer-
ial adapters, a thymidine overhang from the indexed paired-ends
dapters, was conducted at 30 ◦C for 10 min  by adding DNA Ligase
ix  and adapters to the sample DNA. To stop the ligation, Stop
igase Buffer was added into the reaction mixture. AMPure XP
eads were utilized to purify adapter-ligated-DNA products.
.3. Genome ampliﬁcation, building Illumina library and
equencing
Library enrichment was  necessary to maximize the amount of
NA fragments that were attached to adapters (adapter-ligated
NA). PCR Master Mix  was ampliﬁed using a PCR Primer Cock-
ail at 98 ◦C for 30 s for a total of 15 cycles at 98 ◦C for 10 s, 60 ◦C
or 30 s, 72 ◦C for 30 s and a ﬁnal extension at 72 ◦C for 5 min.
he enriched library was puriﬁed by AMPure XP beads followed
y eluting with Resuspension Buffer. To monitor the quality of
he reactions, “in-line” or internal controls were added to the
ample while conducting the end repair, 3′end adenylation and
igation.
DNA quantity and quality control was validated and monitored
y Agilent 2200 TapeStation (Agilent Technologies, Santa Clara,
SA), Qubit 2.0 Fluorometer (Life Technologies, Grand Island, USA)
nd qualitative PCR or qPCR (Applied Biosystems, Foster City, USA)
s seen in Table 2. The Agilent 2200 TapeStation measured con-
entration of all DNA fragments (with and without adapters). The
PCR was conducted with ABI7500 Fast DX (Applied Biosystems,
oster City, USA) following the instructions from KAPA Library
uantiﬁcation Kits (KAPA Biosystems, Woburn, USA). Brieﬂy, trip-
icates of 50, 500, 5000 and 50,000-fold dilutions of each template
ere aliquoted into a 96-well plate. Only the 50,000-fold diluted
NA library was applied in the qPCR plate in parallel with the
tandard controls. The DNA library mixture was denatured at 95 ◦C
or 5 min  followed by ampliﬁcation conditions for 35 cycles at 95 ◦C
or 30 s and 60 ◦C for 45 s. Concentration of the adapter-ligated
NA was calculated using the following formula: [average quan-
ity from ABI7500] × [standard DNA size 452 bp] × [50,000 dilution
actor]/size from TapeStation. The concentration values obtained
rom qPCR were selected to determine the volume of each sample
o pool and make up to 2 nM of library mixtures.
NaOH were added to equal volumes of the DNA libraries for DNA
enaturation, followed by 50-fold dilutions with pre-chilled HT1
uffer to obtain the DNA libraries at 20 pM.  The DNA libraries were
urther diluted to 8 pM with a total volume of 1 ml  with pre-chilled
T1 buffer. One percent PhiX, used as internal control, was  sup-
lemented into the 8 pM denatured DNA solution to observe the
fﬁciency of DNA incorporation during DNA sequencing. Libraries
ere loaded into the cartridge, and sequenced as multiplex two
ead libraries for 308 cycles (including additional 6 cycles of index
eads) according to the manufacturer’s protocol.ical Methods 193 (2013) 394– 404
2.4. Data analysis
The quality of the sequence run was monitored by Sequencing
Analysis Viewer (SAV) (Illumina, Hayward, USA) and by conducting
“resequencing” or aligning of 70 bp–1 Mbp  sequence reads to ref-
erence sequences using MiSeq Reporter (MSR) (Illumina, Hayward,
USA), which used Burrows–Wheeler Aligner (BWA) (Li and Durbin,
2009, 2010). The reads that did not align or aligned to different ref-
erences, were identiﬁed as “unresolved pair.” BWA  adjusts param-
eters based on read lengths and error rates automatically, and then
estimates insert size distribution. The sequence error rate of 3% for a
200 bp and 5% for a 500 bp can be tolerated by BWA. By MSR  default
setting, GATK was utilized for variant calling (DePristo et al., 2011;
McKenna et al., 2010) when BWA  was used for alignment.
A/Brisbane/11/2010 (H3N2) (CY121792–CY121799), A/
California/07/2009 (H1N1), (FJ984386, FJ969827, FJ969529–
FJ969531, FJ969536, FJ969538, and FJ969540), and B/Wisconsin/
01/2010 (CY115183–CY115190) were used for reference-
based alignment. Alignment analyses also included other,
non-inﬂuenza GenBank references, including dengue viruses
DENV-1 (HM469967), DENV-2 (2FJ898452), DENV-3 (FJ744734),
DENV-4 (AY618992), Human enterovirus 71 strain SHAPHC695F/
SH/CHN/10 (JQ736684) and Human betacoronavirus 2c EMC/2012
(JX869059). MSR  generated Bam ﬁles, VCF ﬁles and depth of
coverage (DOC) plots, were used for the identiﬁcation of variants
from the references. Bam and VCF ﬁles were further analyzed
for quality and variance by Integrative Genomics Viewer (IGV)
(Thorvaldsdottir et al., 2012) and notepad++ v.6.3 (Free Software
Foundation, Boston, USA). The percentage of sequence variations
was computed from the number of changed bases divided by total
bases (Table 3).
Statistical analysis was conducted in R Statistical Analysis Envi-
ronment (version 2.15.3). The correlation test used was  ‘Pearson
Correlation’ tool from the website http://www.vassarstats.net/
rdiff.html.
3. Results
3.1. Clinical specimens, molecular diagnosis and cultures
Specimens from six study subjects were selected initially due
to their severe inﬂuenza symptoms. These subjects were selected
from a mixed-age population. The majority (4/6) were children
younger than 15 years old. Only one subject, who was 7 years old,
received vaccination in 2011. None of the subjects were on any
medications prior to sample collection.
The six clinical specimens were conﬁrmed positive for inﬂuenza
virus infection and categorized into speciﬁc types/subtypes
of inﬂuenza using the CDC rRT-PCR assay (Table 1). Out of
ﬁve clinical specimens from Thailand, three (3/5) were pos-
itive for seasonal inﬂuenza A/H3N2 by PCR and two (2/5)
had inﬂuenza B/Yamagata lineage. The specimen collected from
Nepal had 2009 pandemic inﬂuenza H1N1 (pdmH1N1). Only
A/Thailand/VIROAF1/2012 (H3N2) had a Ct value lower than 20.00
during typing and subtyping by CDC rRT-PCR assay. The rest of the
specimens had Ct values higher than 22.00.
After 1–3 passages in MDCK cultivation, virus isolates typing
and subtyping was once again conﬁrmed by CDC rRT-PCR assay
(Table 1). Ct values lower than 16.00 were observed in all virus
isolates.3.2. Quality of processed RNA and DNA samples
Based on MiSeq capability and nature of the samples, the RNA
TruSeq LT Kit was chosen for preparation of the six viral isolates
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as described in Fig. 1. A total of 10.7–15.4 ng/l RNA (both poly
A and non poly A tails) was  obtained from RNA extraction. The
RNA purity, OD260/OD280, measured by NanoDrop was 2.80–2.90.
After the cDNA was synthesized and dsDNA ampliﬁed, the quality
of DNA was  validated by three different measurements: (1) Agi-
lent 2200 TapeStation, (2) Qubit® 2.0 Fluorometer and (3) qPCR as
shown in Table 2. The ﬁnal concentrations and average fragment
sizes measured by Agilent 2200 TapeStation were 216–388 nM
and 233–270 bp, respectively. In addition, quality and quantity
of fragment sizes are displayed compared to standard controls
in the supplemental ﬁgure. The Qubit® 2.0 Fluorometer mea-
sured the overall DNA concentration at 41.4–50.4 ng/l. This DNA
concentration was converted into 235.9–311.6 nM in order to be
compared them with measurements from other equipments. The
qPCR reported size adjusted concentrations of 355.92–616.73 nM.
The Pearson coefﬁcient of determination (R2) values among
the three validated measurements were calculated and compared.
None of the three paired comparisons showed correlation (R2 < 1)
(Data not shown). Compared to the readings from other equip-
ments, the concentration values obtained from qPCR were selected
based on the sequence speciﬁc ampliﬁcation of adapter-ligated
DNA to determine the volume of each sample necessary to pool
2 nM library mixtures. After denaturing and addition of 1% PhiX
internal control, the ﬁnal 8 pM of library mixtures were loaded into
the Illumina cartridge for simultaneous sequencing.
3.3. Sequencing quality and output
The sequencing from Illumina MiSeq Platform yielded a total
of 2.6 Gbases from both Read1 and Read2, which were generated
from a 455 ± 14 K/mm2 cluster density. The quality of the base call-
ing from images and sequences was  determined by quality score
(Q). Approximately 96% of the clusters passed QC ﬁlters and 93.7%
of Read1 and 83.5% of Read2 sequences were ≥Q30  (99.9% accu-
racy of base calling at a particular sequence position). On average,
2.3 Gbases or 88.7% of both reads passed ≥Q30 as shown in Fig. 2a.
The incline curve of %≥Q30 as sequencing progressed from Read1 to
Read2 is shown in Fig. 2b. Additionally, the signal to noise ratio was
6–16, which increased with higher quality base calling or %≥Q30
(Fig. 2c). Less than 1% error rate was  detected in sequences with
60–100% ≥ Q30 (Fig. 2d). A minimal amount of phasing (delayed
sequencing) and prephasing (ahead sequencing) were detected
(0.0281% and 0.1585%, respectively).
3.4. Sequence alignment, DOC and sequence variations
The genomic sequences from the six samples sequenced with
MiSeq were assembled into eight genomic fragments consisting
of (1) PB2, (2) PB1, (3) PA, (4) HA, (5) NP, (6) NA or NA/NB-
additional NB protein (Hatta and Kawaoka, 2003) for inﬂuenza
B, (7) M and (8) NS. Multiple alignments analyses with sequence
references from the most common pathogens found in these
regions were conducted on the samples: seasonal inﬂuenza A
H3N2 strains (A/Brisbane/11/2010), 2009 pandemic inﬂuenza
H1N1 (A/California/07/2009), inﬂuenza B (B/Wisconsin/01/2010)
strains, DENV-1, DENV-2, DENV-3, DENV-4, Human enterovirus
71 strain SHAPHC695F/SH/CHN/10 and Human betacoronavirus 2c
EMC/2012.
Depth of coverage (DOC) for A/Thailand/VIROAF6/2012 (H3N2),
A/Nepal/VIROAF5/2012 (H1N1) and B/Thailand/VIROAF4/2012 as
compared to references A/Brisbane/11/2010, A/California/07/2009
and B/Wisconsin/01/2010 is shown in Figs. 3–5, respectively. The
rest of the DOC graphs for A/Thailand/VIROAF1/2012 (H3N2),
A/Thailand/VIROAF2/2012 (H3N2) and B/Thailand/VIROAF3/2012
are not shown. Overall, the DOC for all six isolates compared to
their matched inﬂuenza references ranged from 600 to 11,000.
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Fig. 2. Quality of sequencing run. (a) a column graph demonstrated numbers of reads (million) that have range of Q Score of 0–40 (Q30 and Q40 were deﬁned as 99.9% and
99.99% accuracy in base calling, respectively). Total of 2.3 Gbases or 88.7% of sequences had Q score equal or greater of 30. (b) A box plot showing % of ≥Q30 as the sequencing
cycles  progress starting from 0 to 308 cycles (Read1: 151 cycles, Index: 6 cycles and Read2: 151 cycles). (c) Dot plot describing the relationship between the % of ≥Q30  and
signal  to noise ratio (calculated from the mean called intensity divided by standard deviation of non called intensities, independent of PhiX and Qscore): the higher % of
≥Q30,  the higher the signal to noise from imaging ﬁles. Range of the signal to noise was noted to be approximately 6–16 with 60–100% of ≥Q30. (d) Dot plot representing a
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he  % of ≥Q30. The error rate observed closer to 0% when the % of ≥Q30 was  closer t
n contrast, the DOC of overall genome against the unmatched
nﬂuenza and non-inﬂuenza strains was less than 10 (data not
hown).
Variations in sequences of the 6 isolates compared to their
atches in eight genomic fragments were further investigated
s described in Table 3. For inﬂuenza A reference (A/Brisbane/
1/2010), the percentages of sequence variations among genes
n A/Thailand/VIROAF1/2012 (H3N2), A/Thailand/VIROAF2/2012
H3N2) and A/Thailand/VIROAF6/2012 (H3N2) were 0.7–1.6%,
.5–1.3%, and 0.8–1.6%, respectively. The A/Nepal/VIROAF5/2012
H1N1) sequence variations from the reference 2009 pan-
emic inﬂuenza A H1N1 A/California/07/2009 were 1.1–1.9%.
equence variations of B/Thailand/VIROAF3/2012 and B/Thailand/
IROAF4/2012 compared to B/Wisconsin/01/2010 were 1.7–4.2%
nd 0.5–1.0%, respectively. Overall, the sequence variations in the
/Thailand/VIROAF3/2012 compared to the referent inﬂuenza B
ere higher than the sequence variations of the other ﬁve samples
ompared to their matched references.ters when compared to the PhiX reference, dependent of PhiX) in relationship with
. The maximum error rate between 60% ≥ Q30 and 100% of ≥ Q30 was less than 1%.
4. Discussion
Six inﬂuenza isolates from MDCK cells were characterized by
CDC rRT-PCR, CPE and HAI and prepared so as to obtain optimal
quantity and quality genomic templates for simultaneous sequenc-
ing by Illumina MiSeq Platform. Several techniques were applied
and investigated thoroughly for sample preparation and charac-
terization. Data analysis from MiSeq Platform identiﬁed efﬁciently
seasonal inﬂuenza A H3N2, 2009 pandemic inﬂuenza A H1N1 and
Inﬂuenza B from the DNA library mixtures.
Optimal DNA quality and quantity were essential for the suc-
cessful NGS platform sequencing, as has been demonstrated in
previous studies (Hoper et al., 2011; Kampmann et al., 2011; Kuroda
et al., 2010). We utilized several methodologies to ensure optimal
nucleic acid quantity and quality. The Ct values from the typing
and subtyping CDC rRT-PCR assays were utilized to estimate the
initial amount of viral templates. Three direct nucleic acid mea-
surements (2200 TapeStation, Qubit and qPCR) were conducted
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Fig. 3. Depth of coverage plots (DOC) of A/Thailand/VIROAF6/2012 (H3N2) aligned with A/Brisbane/11/2010 (H3N2). Genomic fragments are arranged according to sizes as
follows: (a) PB2, (b) PB1, (c) PA, (d) hemagglutinin (HA), (e) nucleoprotein (NP), (f) neuraminidase (NA), (g) matrix (M), and (h) NS. Position from 5′ to 3′ was plotted in X axis
and  DOC was plotted in Y axis.
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Fig. 4. Depth of coverage plots (DOC) of A/Thailand/VIROAF5/2012 (H1N1) aligned with A/California/07/2009 (H1N1). Genomic fragments are arranged according to sizes as
follows: (a) PB2, (b) PB1, (c) PA, (d) hemagglutinin (HA), (e) nucleoprotein (NP), (f) neuraminidase (NA), (g) matrix (M), and (h) NS. Position from 5′ to 3′ was  plotted in X axis
and  DOC was  plotted in Y axis.
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Fig. 5. Depth of coverage plots (DOC) of B/Thailand/VIROAF4/2012 aligned with B/Wisconsin/01/2010. Genomic fragments are arranged according to sizes as follows: (a)
PB2,  (b) PB1, (c) PA, (d) hemagglutinin (HA), (e) nucleoprotein, (f) NB protein and neuraminidase (NBNA), (g) matrix (M), and (h) NS. Position from 5′ to 3′ was plotted in X
axis  and DOC was  plotted in Y axis.
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Table 2
Measurements of quantity of DNA by three different procedures: Agilent 2200 TapeStation, Qubit® 2.0 Flurometer and qPCR in comparison to Ct values by CDC rRT-PCR and sequence reads output from MiSeq rt-PC.
No. Namea Ct MiSeq totalb
and medianc
mapped
coverage reads
2200 TapeStation Qubit qPCR
Avg.
fragment
length
Conc.
reading
(nM)
Actual
conc.
(nM)d
Conc.
reading
(ng/l)
Actual
conc.
(nM)e
Average
conc.
reading
(pM)
STDEV of
conc.
reading
Coefﬁcient of
variance (%CV)
of 3 readings
nM
stock
Size-adjusted
actual conc.
(nM)f
1 A/Thailand/VIROAF1/2012 13.8/13.92 736,862/930.7 270.0 6.15 246.0 41.4 235.9 4.3 0.3 7.0% 212.6 355.9
2  A/Thailand/VIROAF2/2012 14.07/14.01 640,095/830.7 237.0 5.39 215.6 44.6 289.5 5.8 0.1 2.0% 287.9 549.1
3  B/Thailand/VIROAF3/2012 13.42 736,990/2513.2 262.0 9.71 388.4 50.4 295.9 5.3 0.8 15.0% 264.0 455.5
4  B/Thailand/VIROAF4/2012 13.35 759,421/2884.9 243.0 6.24 249.6 46.7 295.6 6.6 0.1 1.0% 331.6 616.7
5  A/Nepal/VIROAF5/2012 14.07/15.98 720,901/1268.4 251.0 8.33 333.2 43.2 264.7 5.1 0.2 5.0% 257.1 463.0
6  A/Thailand/VIROAF6/2012 13.5/13.55 714,912/1701.1 233.0 6.31 252.4 47.2 311.6 5.2 0.2 4.0% 260.7 505.7
a Sequences of I7 indexes for VIROAF1, VIROAF2, VIROAF3, VIROAF4, VIROAF5 and VIROAF6 are A002, A004, A005, A006, A007 and A012 are CGATGT, TGACCA, ACAGTG, GCCAAT, CAGATC and CTTGTA, respectively.
b Number of total mapped sequence reads that passed QC ﬁlter (≥QC30).
c Median mapped sequence coverage observed throughout the genome.
d Concentration used to calculate R2, the Pearson coefﬁcient of determination, in correlation with the MiSeq coverage and yielded R2 equal to 0.400.
e Concentration used to calculate R2, the Pearson coefﬁcient of determination, in correlation with the MiSeq coverage and yielded R2 equal to 0.551.
f Concentration used to calculate R2, the Pearson coefﬁcient of determination, in correlation with the MiSeq coverage and yielded R2 equal to 0.491.
Table 3
Numbers of sequence variations from matched references.
No Name References Number of sequence variations difference from matched referencesa Total of variation of bases from the reference/total bases (%)
(1) PB2 (2) PB1 (3) PA (4) HA (5) NP (6) NA or NBNA (7) M (8) NS
1 A/Thailand/VIROAF1/2012 Inﬂuenza A (A/Brisbane/11/2010)b 32/2308 (1.4%) 17/2309 (0.7%) 17/2208 (0.8%) 27/1732 (1.6%) 11/1538 (0.7%) 12/1444 (0.8%) 8/1003 (0.8%) 6/865 (0.7%)
2  A/Thailand/VIROAF2/2012 Inﬂuenza A (A/Brisbane/11/2010)b 17/2308 (0.7%) 21/2309 (0.9%) 10/2208 (0.5%) 22/1732 (1.3%) 9/1538 (0.6%) 12/1444 (0.8%) 7/1003 (0.7%) 9/865 (1.0%)
3  B/Thailand/VIROAF3/2012 Inﬂuenza B (B/Wisconsin/01/2010)c 39/2358 (1.7%) 99/2330 (4.2%) 92/2255 (4.1%) 41/1789 (2.3%) 53/1762 (3.0%) 41/1512 (2.7%) 21/1151 (1.8%) 23/1063 (2.2%)
4  B/Thailand/VIROAF4/2012 Inﬂuenza B (B/Wisconsin/01/2010)c 12/2358 (0.5%) 14/2330 (0.6%) 20/2255 (0.9%) 11/1789 (0.6%) 12/1762 (0.7%) 11/1512 (0.7%) 11/1151 (1.0%) 6/1063 (0.6%)
5  A/Nepal/VIROAF5/2012 2009 pdm H1N1 (A/California/07/2009)d 26/2280 (1.1%) 24/2274 (1.1%) 27/2151 (1.3%) 33/1701 (1.9%) 23/1497 (1.5%) 15/1410 (1.1%) 11/982 (1.1%) 13/863 (1.5%)
6  A/Thailand/VIROAF6/2012 Inﬂuenza A (A/Brisbane/11/2010)b 28/2308 (1.2%) 21/2309 (0.9%) 23/2208 (1.0%) 27/1732 (1.6%) 10/1538 (0.7%) 15/1444 (1.0%) 8/1003 (0.8%) 11/865 (1/3%)
a Numbers of Variations/total bases.
b Total bases for A/Brisbane/11/2010 strain: PB2(2308), PB1(2309), PA(2208), HA(1732), NP(1538), NA(1444), M(1003) and NS(865).
c Total bases of B/Wisconsin/01/2010 strain: PB2(2358), PB1(2330), PA(2255), HA(1789), NP(1762), NA(1512), M(1151) and NS(1063).
d Total bases of A/California/07/2009: PB2(2280), PB1(2274), PA(2151), HA(1701), NP(1497), NA(1410), M(982) and NS(863).
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E., Nielsen, L.P., Gilbert, M.T., 2011. A simple method for the paral-W.  Rutvisuttinunt et al. / Journal of V
n all samples. Despite the lack of correlation (R2 < 1) among the
aired comparisons, qPCR was selected due to its speciﬁcity in mea-
uring the concentration of adapter-ligated-DNA. No signiﬁcant
ifferences were found among them (p > 0.05). More measure-
ents using these methods are required to increase the power of
ata analysis to determine which methodology should be used to
repare the library for sequencing.
Although the MiSeq highest optimal capacity was  15 pM DNA
f template, 8 pM of library mixtures was chosen for sequencing.
his mid  range DNA template yielded approximately 2.6 Gbases
f sequencing data with 85% of sequences having ≥Q30 accu-
acy. Although the cluster density of 455 ± 14 K/mm2 fell in the
ower range of Illumina’s suggested optimized cluster conditions
400–1100 K/mm2), this information provided high DOC (>600)
ith 99.9% accuracy (≥Q30) for the complete inﬂuenza genomes
f all six samples (data not shown).
Our study was able to sequence complete genomes of seasonal
nﬂuenza A H3N2, 2009 pandemic inﬂuenza A H1N1 and inﬂuenza
 with at least 5–30-fold higher DOC than what has been reported
sing different platforms (Hoper et al., 2011; Kampmann et al.,
011; Kuroda et al., 2010). In addition, the DOC of PA, PB1 and PB2
ragments were not the lowest compared to other fragments as
entioned previously by Kampmann et al. and Kuroda et al. No
ragments bias of DOC and no correlation of fragment length with
OC were observed in our study.
In addition, multiple sample characterizations were conducted
o minimize false identiﬁcation and categorize the samples specif-
cally. Both inﬂuenza and non-inﬂuenza reference sequences from
ommon pathogens found in this region from GenBank were uti-
ized for sequence alignment analysis. Based on multiple alignment
nalyses of our samples, at least 100-fold DOC on matched refer-
nces was observed, which was higher than unmatched references.
he sequencing from MiSeq showed the majority of viral isolates
ere three seasonal inﬂuenza A H3N2 strains, one 2009 pandemic
nﬂuenza A H1N1 strain and two Inﬂuenza B strains. These results
ere in agreement with CDC rRT-PCR and HAI assays on clinical
amples and viral isolates, respectively (Table 1).
Furthermore, the ultra depth of sequence reads from NGS yield-
ng high resolution that can quantify accurately variants in mixed
nﬂuenza virus populations detected by Sanger and pyrosequenc-
ng methods (Ghedin et al., 2009). NGS has demonstrated its ability
o identify inﬂuenza A H3N2, inﬂuenza A H1N1 and inﬂuenza B from
ixed virus pools created artiﬁcially in equal ratios (unpublished
ata) and further detect rare variants of West Nile virus and HIV-1
Macalalad et al., 2012). The study of variants in inﬂuenza virus by
GS will improve the capacity to monitor the emergence of anti-
enic, drug-resistant or pandemic strains that originate possibly
rom inﬂuenza host switching.
Sequence variations analysis detected the highest percent-
ge of variance in B/Thailand/VIROAF3/2012 (Table 3) compared
o reference inﬂuenza B (B/Wisconsin/01/2010). One possi-
le factor which distinguished this sample from the others
as vaccination history. The study subject VIROAF3 received
nﬂuenza vaccination in Sep 2011 containing antigens from
/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2)-like virus
nd B/Brisbane/60/2008 (inﬂuenza B in Victoria lineage). In addi-
ion, during initial observations, viral subpopulations in the viral
solates cultured from the unvaccinated individuals were observed
t various sites in the NP and NA genes of VIROAF1, in the HA
ene of VIROAF2 and in the PA gene in the VIROAF4 (data not
hown). Whether these observations are consistent will require
urther investigation.
In summary, the NGS MiSeq Platform can identify and obtain
omplete sequence information from seasonal Inﬂuenza A H3N2,
009 pandemic inﬂuenza A H1N1 and inﬂuenza B present in
NA library mixtures. The MiSeq Platform’s high sensitivity alsoical Methods 193 (2013) 394– 404 403
increases the accuracy of the sequence obtained compared to more
traditional molecular and sequence methods. The high coverage
and low false identiﬁcation suggests that the NGS MiSeq Platform
improved procedures signiﬁcantly in identifying inﬂuenza virus
distribution from mixtures. The NGS MiSeq Platform technique
can be more cost-effective if maximized to 12 samples in the DNA
library mixtures, the maximum capacity of MiSeq. Further reﬁne-
ment in increasing assay sensitivity with lower viral templates
would make the MiSeq Platform a practical tool for viral diagnosis
and characterization.
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